Summary Acquired resistance to anthracyclines is characterised by a lower sensitivity to these agents, associated with impaired accumulation of drug. We have examined the ability of aclacinomycin A (ACM) associated with doxorubicin (DOX), to increase intranuclear DOX concentrations and, consequently, to enhance cytotoxic effects against drug resistant cells in vitro. A recently developed microspectrofluorometric technique is used to measure intranuclear DOX concentrations in sensitive and DOX-resistant K562 cells treated with DOX and ACM. Fluorescence emission spectra are collected from a microvolume of single living cell nuclei. From both DOX and ACM model fluorescence spectra (free, DNA-bound and metabolites), the intranuclear spectral profile is analysed according to the amount of each component. This quantitative analysis determines intranuclear DOX concentrations with an error of 10%. Non-cytotoxic doses of ACM, in combination with DOX, increase cytotoxic activity of DOX against K562 resistant cells. When DOX-resistant cells are exposed simultaneously to ACM and DOX, significant increases in intranuclear DOX concentrations are found compared with the case of exposure to DOX alone. The measure of the intranuclear retention of DOX shows that ACM partly blocks the DOX efflux in resistant cell nuclei, resulting in enhanced accumulation of DOX. These data lead us to conclude that ACM-DOX association partly reverses the DOX resistance at clinically achievable concentrations.
A major obstacle to successful use of anthracyclines and other cytotoxic drugs in cancer chemotherapy is the development of clinical drug resistance. Tumour cell modifications (resulting in multidrug resistance) are characterised by a complex phenotype of cross-resistance to antineoplasic agents Bradley et al., 1988) . These are accompanied by gene amplification, a deficient accumulation of drug, an enhanced drug efflux function and a build up of an integral membrane glycoprotein with a molecular weight of 170,000-180,000 (P-glycoprotein) . A study with DNA transfectants (Riordan et al., 1985) has demonstrated that the P-glycoprotein was intimately involved in resistance and might be serving as an active efflux pump to remove the drug from the cell. One way to overcome in vitro resistance to anti-cancer drugs has been to use simultaneously calcium channel blockers (Tsuruo et al., 1983) or calmodulin inhibitors (Ganapathi et al., 1984) together with the anti-cancer drug. The mechanism of the resistance reversal appears to be related to the inhibition of outward drug transport which subsequently leads to increased intracellular drug levels.
With the recent development of microspectrofluorometry, we have studied fluorescence signals from microvolumes within a single living cell (Ginot et al., 1984; Manfait et al., 1987) . DOX concentrations in nuclei of sensitive and DOXresistant K562 human leukaemia cell lines may thus be determined . We have demonstrated the importance of the intranuclear concentration, since the cytotoxic effect induced by DOX was dependent on the amount of drug actually incorporated into the nucleus .
A previous report showed that high ACM levels (10pgrml'), in combination with DOX or daunomycin, increased the intracellular amount of the latter compounds with concomitant increased cytotoxicity against resistant cells (Tapiero et al., 1988) . In this paper, we have extended these inhibition growth studies with non-toxic doses of ACM against DOX-resistant K562 cells in order to determine which kind of exposure with ACM and DOX, simultaneously or sequentially, produced the most cytotoxicity. To (Lozzio & Lozzio, 1975 (Tsuruo et al., 1986; Sugimoto & Tsuruo, 1987 (Ginot et al., 1984; Millot et al., 1989 ).
An optical microscope (Olympus BH2) equipped with a 100 x water immersion objective (Leitz Fluotar) 
Microspectrofluorometric measurements
For the microspectrofluorometric analysis, the cells were incubated in the medium containing DOX and ACM. Then they were washed free of drug in cooled PBS at 4°C and seeded in a Petri dish containing PBS. These survival conditions without glucose decrease the energy metabolism and the active outward transport of resistant cells. By repeated measurements at 37°C, at regular intervals for more than 1 h, on the same location on a single cell nucleus, a decrease of intranuclear DOX concentration could also be detected for K562 and K562-DOX cell lines. The results of the above measurements are represented by the following equation:
Where C is the intranuclear DOX concentration depending on time t, which is expressed in minutes.
All data reported in this work have been collected from a sample of 20-30 different cell nuclei within the first 15 min after transferring cells in PBS. Under these experimental conditions, the intranuclear concentrations remained essentially unaffected (of the order of 5%) during the total time interval within these limits. Twenty spectra from the same intracellular location were accumulated in order to increase the signal to noise ratio. Sample heating and photobleaching were found to be negligible under our experimental conditions. A light power of 4 yW at the sample and an illumination time of 1 s were used. Cells always remained viable after repeated fluorescence measurements as determined by phase contrast microscopy. Spectra were numerically corrected for the photodiode array response due to small differences in the quantum yield of each diode and for the transmission of the interference filter.
Laser power and instrumental resp onse were controlled by the daily use of rhodamine B (C= 70 nM in ethyl alcohol solution) as an external standard.
Determination of the DOX concentration in living cell nuclei
The fluorescence signal at a given wavelength, arising from the nucleus of a cell treated with DOX F(A), can be expressed as a sum of spectral contributions of free DOX, DNA-bound DOX and an intrinsic nuclear signal, i.e.
F (1) , we have shown that each of these contributions has a characteristic spectral shape determined independently by studies of aqueous solutions. Reference spectra, corrected for buffer contribution, for free DOX (0.12 tM) (Ff) in PBS solution and DOX (2pM) bound to DNA (concentration in phosphate: 1 mM) in PBS (Fb) are presented in Figure 1 , after normalisation of the integrated surfaces. The fluorescence yield of DOX in the free form is higher than that of the bound form by a factor 48 ± 2.
For simultaneous incubation with ACM and DOX, the intranuclear spectral analysis must take into account two additional contributions derived from the following compounds: (i) ACM; and (ii) 7-deoxyaklavinone, termed C,. The fluorescence yield of free ACM (5 x 10-M) is 200 times higher compared to the ACM (5 x 10-M) bound to DNA (1 mM) (Manfait et al., 1988) . C,, one intracellular metabolite from ACM with an altered chromophore, results from an enzymatic cleavage of the trisaccharide and has been isolated Free ACM (0.5 IiM) (*), C, (0.5 fiM) (-) . Laser excitation wavelength: A = 457.9 nm, laser power at the sample: 4 ItW. and identified by HPLC (Ogasawara et al., 1981; Egorin et al., 1982) and microspectrofluorometric studies. Thus, equation (2) A fluorescence emission spectrum, as determined from a selected microvolume in the nucleus of a K562 cell after a simultaneous exposure with ACM and DOX, is shown in Figure 2 . The resolution into five components (free DOX, bound -DNA DOX, ACM, C, and the intrinsic nuclear contribution), leading to the computed DOX concentration, is also shown in Figure 2 . Notice that the free DOX contributes about one-quarter of the total DOX signal, although this species only constitutes 0.2% of the total drug concentration. This result is general for K562 and K562-DOX cell lines and for the investigated range of drug concentrations in the medium .
Results
Effect of ACM on DOX-induced growth inhibition in sensitive and resistant K562 cells The growth inhibition following 4 h exposure to ACM or DOX was determined as reported in the Materials and methods section. Table I shows the growth inhibitory activity of ACM and DOX on K562 and K562-DOX cells. K562-DOX cells, selected for 25-fold resistance to DOX, were 7-fold resistant to ACM, when compared with the GI50 of both cell lines.
To detect a synergy mechanism between ACM and DOX on cellular toxicity, cells were incubated for 4h in DOX without and with non-toxic ACM concentrations (growth inhibition < 5%): 10nM for K562, 50nM for K562-DOX. Growth of both cell lines was evaluated by their cellular doubling number. Cytotoxic effects of each incubation process are compared in Figure 3 . For the K562 line, simultaneous incubation with DOX and a non-toxic ACM dose (10 nM) did not produce any enhancement of the DOX cytotoxicity. On the contrary, for the resistant line, incubations with DOX and a non-toxic ACM dose (50nM) promoted a partial restoration of the DOX activity. For example, DOX (2,000 nM) associated with ACM (50 nM) gives a similar toxicity to DOX (3,000 nM) alone. In this case, ACM (50 nM) allows a DOX dose decrease of 33%, which corresponds to a partial reversal of anthracycline resistance.
K562-DOX cells have been exposed to ACM and DOX, according to two different associations in order to compare their cytotoxic activity: (i) simultaneous exposures with ACM and DOX and (ii) ACM pretreatments followed by DOX alone (Figure 4 ). For each incubation process, the concentration ratio ACM/DOX = 1, and the exposure time to each drug is 1 h. Compared to the ACM pretreatments, simultaneous exposures to both anthracyclines produced higher cell growth inhibitions. This observation became more evident for ACM and DOX doses superior to I tIM.
A synergistic effect between DOX and ACM against K562-DOX cells can be justified on the basis of deviations from the expected additive cytotoxicity determined with each drug used alone and represented by an isobologram (Steel et al., 1979) . Since the dose-response curves of ACM and DOX are non-linear, the expected additive GI50 of K562-DOX cells is represented on an isobologram as shown in Figure 5 , corresponding to 4 and 1 h exposure time respectively. This isoeffect plot is defined from the ACM and DOX doses that give growth inhibitory values that add up to the level GI50. The addition is performed by taking the increments in DOX doses starting from zero for calculation by mode I, and from the GIso for calculation by mode II (Steel et al., 1979) . The datum from Figure 3 corresponding to an exposure of K562-DOX cells to DOX (1,500 nM) and ACM (50 nM) (GI5o at 4 h) has been reported on the isobologram (Figure 5a) . This point appears on the left of the envelope of additivity and could be interpreted in terms of a cytotoxic potentiation mechanism between ACM and DOX against K562-DOX cells. The point from Figure 4 corresponding to a simultaneous exposure with DOX (1,000 nM) and ACM (1,000 nM) (GI50 at 1 h) is reported in Figure Sb and confirms this conclusion. In contrast the point from Figure 4 corresponding to a sequential exposure with ACM (3,000 nM) fol- GIoo (nM) 200 5000 800 1400 Growth inhibition was determined on cells exposed for 4 h to a given drug concentration, and resuspended for 3 days in drug-free medium. Growth inhibition was calculated as per cent ratio between doubling number of treated cells and doubling number of untreated cells. Growth inhibitory concentrations were calculated from three to five independent determinations. Each standard deviation was less than 15% of the average. Effect of ACM on the intranuclear DOX uptake A previous study reported that DOX cytotoxicity was dependent on the drug concentration in nuclei and that the resistant K562 subline exhibited an altered DOX uptake . To determine whether co-incubation with ACM produces an enhancement of DOX intranuclear concentration, we have measured intranuclear concentrations of DOX by microspectrofluorometry, as a function of extracellular doses of ACM. This relationship is shown in Figure 6 . For K562-DOX cells, after 4 h of incubation with ACM and DOX (1 JAM), DOX intranuclear concentrations were increased proportionally to ACM extracellular doses. In contrast, for the sensitive line, the DOX uptake into the nucleus was found to be independent of the ACM dose in the medium.
DOXORUBICIN RESISTANCE REVERSAL BY ACLACINOMYCIN
The time-course of DOX intranuclear uptake and the effect of ACM (1 JAM) on this process is shown in Figure 7 Figure 8 . When CO is the initial intranuclear DOX concentration of preloaded cells, the DOX concentration (C) retained inside the nucleus in the presence of DOX-free medium is described by an exponential decrease:
Where t is time and T1/2 is the time corresponding to decrease of the intranuclear DOX concentration. DO) from resistant cells (T1/2= 30 min) occurs faster tha from sensitive cells (T1/2 = 8 h). The presence of ACM during the DOX efflux phase increased the DOX rel from K562-DOX cell nuclei (T1/2 =90 min), but did no' the efflux from the nuclei of sensitive cells.
A more detailed study of DOX uptake and retenti4 explain the weaker efficiency of sequential exposures to followed by DOX, compared to simultaneous exposi both drugs, which have been reported in the Effect of on DOX-induced growth inhibition section. DOX uptakes in resistant cell nuclei are compared in Figure 9 , as a function of the time, according to the type of incubation with associated DOX and ACM. DOX was permanently present in the medium, but ACM was added with various delays. DOX concentration values, as determined from 30 measurements. (Tsuruo et al., 1983; Friche et al., 1987) , calmodulin antagonists (trifluoperazine, perhexilene maleate) (Ganapathi et al., 1984) , triparanol analogues (tamoxifen) (Ramu et al., 1984) , cardiac anti-arhythmics (quinidine, amiodarone) (Chauffert et al., 1986; Tsuruo et al., 1984) and cyclosporins (Twentyman, 1988) .
ACM, an antineoplasic agent (Umezawa et al., 1987) , has been shown to circumvent anthracycline resistance at the high dose of 10 pgml-l (Tapiero et al., 1988) . Moreover, a significant synergistic effect of cytotoxicity against P388 leukaemia has been observed with the associations ACM-cyclophosphamide and ACM-vincristine (Fugimoto et al., 1979) . Compared with other drug combinations used to reverse the resistance, the interest in ACM is because of its own significant activity against a number of human tumours and its current use in clinical investigations (Kumai et al., 1984; Majima et al., 1987 (Egorin et al., 1982) . These short-term incubations probably reflect, better than continuous incubations, the in vivo plasma conditions following a bolus injection. In these incubation conditions, an ACM dose which alone does not produce any growth inhibition on DOX resistant cells, does induce a partial reversal of DOX resistance.
As for other agents that reverse r -sistance to DOX, the possible mechanism of this synergistic effect could depend on increased uptake of DOX induced by ACM in resistant cells. The mechanism of DOX action has been attributed to intercalation with DNA (Manfait et al., 1982) with the result that DNA replication and RNA synthesis is inhibited (Zunino et at.,1980), strand-breaking of DNA by bioreductive alkylation occurs (Moore, 1977) and oxygen-free radicals are generated (Bachur et al., 1979) . Although the relationship between the cytotoxic effect of DOX with total cellular drug content is unclear (Lane et al., 1987) , we have shown previously a direct relationship between the growth inhibition effect and the DOX amount actually in the nucleus . Our findings suggest that there is an enhancement of DOX cytotoxicity with increased intranuclear concentration of this drug induced by ACM. The combined effect of these independent observations strongly supports the hypothesis that the nucleus is a target for DOX.
Three hypotheses could explain the increase of the amount of intranuclear DOX caused by ACM: (i) an alteration of DOX influx, (ii) an alteration of DOX efflux, or (iii) a redistribution of DOX inside the cell, allowing it to reach targets more conducive to cytotoxicity. In the light of data implicating increased activity of a membrane-associated pump called P-glycoprotein in acquired resistance, particular attention was given to drug efflux out of the nucleus in our system. With direct observation inside the nucleus of living cells, using microspectrofluorometry, we show that DOX is bound to DNA by a reversible interaction. The DOX efflux from the nucleus occurs faster in K562-DOX cells compared to sensitive cells, with the result that resistant cells are able to reduce intranuclear DOX concentrations to sublethal values by active efflux.
This study demonstrates that the presence of ACM blocks the DOX efflux in the resistant cell line, resulting in enhanced accumulation of DOX and increased cytotoxicity. Because of the rapid accumulations of ACM into sensitive and multidrug resistant lines (Seeber et al., 1980; Tapiero et al., 1988) , the ACM intracellular deposition might in turn affect the DOX efflux. In contrast, another agent (forskolin) which reversed resistance to DOX, with increase of DOX cellular amounts, has virtually no effect on the rate of drug efflux (Wadler & Wiernik, 1988) . The exact function of Pglycoprotein is not well known; however, a recent study has demonstrated drug binding to this protein (Cornwell et al., 1986) , suggesting its involvement in drug transport. So, the altered efflux of DOX by ACM in resistant cells could result from a molecular interaction between ACM and the Pglycoprotein or from an altered expression of this protein.
In conclusion, our results indicate that ACM partly reverses DOX-resistance at clinically achievable concentrations. We find that the reversal of resistance induced by ACM, associated with the DOX efflux inhibition, is reversible and requires the continuous presence of ACM in the medium. Thus, toxicologic, pharmacokinetic studies and clinical trials as resistance modifiers are now in progress by using the ACM-DOX association in simultaneous injections.
